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Abstract 
A family of original bis(artemisinin-NHC)gold(I) complexes have been synthesized. These 
hybrid molecules combine two biological active motifs, an artemisinin derivative (DHA) 
and a cationic bis(NHC)gold(I) unit. One of these complexes, complex 2a, has been analyzed 
by single-crystal X-ray diffraction and tested in depth for its anticancer properties. Complex 
2a shows strong anticancer activities on a representative panel of human cancer cell models 
from 8 different localizations (prostate, breast, lung, liver, bladder, bone, acute and chronic 
myeloid leukemias). Complex 2a shows anticancer activity to a much better degree than 
Auranofin and DHA standards with GI50 values in nM range, together with a superior 
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selectivity in regard to non-cancer cell models. Next to expected ROS formation and TrxR 
inhibition, an original and distinctive mechanism of action through inhibition of NRF2 ³ a 
transcription factor strongly associated with aggressiveness and resistance to cancer 
therapies ³ with an IC50 value at nM range has been evidenced. Importantly, the NRF2 
inhibitory effect of complex 2a could remarkably sensitize to sorafenib in HepG2 liver cells, 
in which dysregulated NRF2 signaling is known to be associated with primary and acquired 
drug resistance. Moreover, complex 2a also inhibited NF-NB and HIF transcriptional 
activities, which are also linked to progression and resistance in cancer. Our findings 
provide experimental evidence that hybrid (NHC)gold(I) molecules ³such as complex 2a 
³ represent a new class of organometallic hybrid molecules that may yield new therapeutic 
agents. 
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Introduction 
Artemisinin and its derivatives represent the most important class of drugs to combat 
malaria nowadays. During the period from 2010 to 2017 the number of deaths worldwide 
caused by malaria decreased by 28% mainly due to the use of artemisinin-based 
combination therapies 1. Nevertheless, the interests on artemisinin derivatives is not only 
focused on malaria, it has been shown that these compounds show interesting activities 
against viral diseases and cancer 2, 3, 4, 5. In the context of cancer, one mechanism of action is 
based on ROS formation, due to an activation of artemisinin derivatives by iron from free 
heme 5, 6, 7, 8. This activation takes mainly place in mitochondria, where fresh heme is 
produced continuously. It has been evidenced that mitochondria-targeting artemisinin 
derivatives show stronger anticancer activities than non-mitochondria-targeting ones 6. 
Another class of molecules, cationic N-heterocyclic carbene (NHC) gold(I) complexes show 
also solid anticancer activities and the main mechanism of action discussed concerns 
apoptosis due to an antimitochondrial activity of such complexes 9, 10, 11, 12. During the last 
few years we focused our research on the optimization of NHC gold(I) complexes for 
anticancer activities 13, 14, 15. Herein we present the synthesis, cytotoxic, selectivity and 
mechanistic studies of cationic bisNHC gold(I) complexes incorporating an ether derivative 
of dihydroartemisinin (DHA, semi-synthetic derivative of artemisinin and metabolite of all 
artemisinin compounds) as building block. 
 
  
  4 
Results 
In order to fuse DHA and NHCs precursors we used aliphatic linkers of different 
lengths C3 to C5. The synthesis (Figure 1) starts with the formation of an ether, by reacting 
commercially DHA with a bromoalcohol in the presence of boron trifluoride etherate 
catalyst according to the procedure described by Haynes for the C3-derivative, leading to 
the single E-isomers DHA-C3 to DHA-C5 16. The next step was the reaction between the 
bromoalkyl DHA derivatives and methyl imidazole in order to obtain the corresponding 
carbene precursors 1a to 1c with yields ranging from 39 to 92%. The formation of the target 
gold complexes has been achieved by two approaches. For the C3 derivative, the convenient 
transmetalation route involving the mild base Ag2O, followed by an ion exchange with 
AgNO3 and subsequent addition of Au(SMe2)Cl has been used. For the C4 and C5 
derivatives, the direct metalation involving K2CO3 and Au(SMe2)Cl has been applied. The 
gold(I) complexes 2a-c were isolated after purification by chromatography as white solids 
with yields of 31 to 84%. All compounds were characterized by 1H and 13C NMR 
spectroscopy, high-resolution mass spectrometry and elemental analysis (see the 
Supporting Information). 13C NMR spectroscopy unequivocally evidences the formation of 
the cationic gold(I) complexes with resonance of the carbenic carbons located at 183.6-183.7 
ppm. HRMS spectra of 2a-c exhibit the classical peak for the cationic fragment [M ² X-]+ and 
elemental analysis correspond to the general [AuL2][X] formula. Moreover, single crystals 
suitable for X-ray structure analysis have been obtained by gas phase diffusion from diethyl 
ether to a saturated solution of 2a in acetonitrile (Figure 1). In the solid state the gold(I) 
shows the typical linear coordination stabilized by two NHC ligands. The NHC planes are 
crossed around the C-Au-C axis with torsion angles from 116° to 138°. It is remarkable that 
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the bulky DHA-derivative groups are on the same side of the central bisNHC gold motif. 
This is due to an aurophilic interaction leading to a dimeric form in the solid state of the 
complex with Au-Au distance of 345.0 pm.  
 
 
Figure 1. On the top: synthesis of proligands 1a-c and gold(I) complexes 2a-c. On the bottom is depicted the 
structure of the cationic part of 2a in the solid state. One bisNHC gold unit looking along the C-Au-C axis on 
the left and dimeric arrangement on the right. 
 
In a first anticancer screening, precursors 1a-c and complexes 2a-c were evaluated for 
their in vitro cytotoxic abilities against the PC-3 prostate cancer cell line and two non-cancer 
cell lines (NIH3T3 fibroblastic and RPWE-1 epithelial prostatic cell lines) (Table 1). 
Interestingly, the imidazolium salts 1a-c showed no cytotoxic effects (GI50 > 20 µM), while 
complexes 2a-c exhibited strong antiproliferative activities with GI50 values between 20 nM 
and 70 nM. The selectivity indexes (SI = GI50 (non-cancer cell line) / GI50 (cancer cell line)) 
of 2a-c gave nearly the same values concerning NIH3T3 cells ranging from 15.5 to 16.7, while 
RPWE-1 cells gave a more differentiated result with the highest SI = 6.9 for 2a.  
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Table 1. Cytotoxicity and selectivity of compounds 1a-c and 2a-c on PC-3 prostate cancer cells versus non 
tumoral NIH3T3 mouse embryonic fibroblasts and RWPE-1 human prostatic epithelial cells (GI50 [µM], 72 h, 
MTT assay).[a] 
 
 PC-3 NIH3T3 SI[b] RWPE-1 SI[b] 
1a > 20 > 20 - > 20 - 
1b > 20 > 20 - > 20 - 
1c > 20 > 20 - 3.74 - 
2a 0.070 1.13 16.2 0.480 6.9 
2b 0.042 0.700 16.7 0.110 2.6 
2c 0.020 0.310 15.5 0.098 4.9 
Auranofin 1.09 1.10 1.0 0.084 0.1 
DHA 1.56 3.86 2.5 9.68 6.5 
3 0.695 7.98 11.8 0.112 0.1 
3 / DHA (1:2) 1.09 2.85 2.6 0.218 0.2 
 
[a] The GI50 values represent the concentration of compound causing 50% inhibition of cell growth.  
Mean of at least three independent experiments.  
[b] Selectivity index ((SI = GI50 (non-cancer cell line) / GI50 (cancer cell line)). 
 
As reference drugs for our studies, along with DHA, we tested the gold complex 
auranofin, used for treating inflammatory arthritis, and now proposed for drug repurposing 
in cancer 17, which recently entered phase I/II trials in lung cancer in combination with 
mTOR inhibitor sirolimus (Clinicaltrials.gov ID NCT01737502). Moreover, a published 
cationic bisNHC gold(I) complex 3, containing a methyl and a quinoline substituents 18, and 
a mixture of 3 and DHA (1:2) were investigated in order to evaluate the potential synergism 
effect of the hybrid complexes. Outstandingly, complexes 2a-c displayed 16 to 55-fold and 
22 to 78-fold higher potency than auranofin and DHA on PC-3 cells, respectively. Moreover, 
they were 6.2 to 16.7 more selective towards cancer cells than NIH3T3 compared to the two 
drug references. Remarkably, complex 2a shows a PC-3/RPWE-1 SI value close to that of 
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DHA but 69 times higher than that obtained for both gold references, auranofin and 
complex 3. Complex 3 showed 10 to 35-fold lower activity than 2a-c and the mixture of 3 
and DHA has an efficiency between DHA and 3 with a low selectivity. Overall, these results 
highlight that linking a derivative of DHA on the NHC scaffold of a bisNHC gold(I) unit 
results in an effect characterized by a high cytotoxicity combined with a high selectivity. 
Due to its better selectivity, complex 2a was chosen for further biological 
investigations. Besides PC-3 prostate cancer, 2a was thus tested on a panel of seven other 
representative human cancer cell models, namely A549 (lung), U-2 OS (bone), MCF-7 
(breast), T24 (bladder), LAMA (chronic myeloid leukemia), HL-60 (acute myeloid leukemia) 
and HepG2 (liver). An additional noncancerous cell line, the MC3T3 pre-osteoblastic cell 
line was also tested (Table 2).  
 
Table 2. Cytotoxicity of complex 2a, auranofin, DHA, complex 3 and a mixture of complex 3 and DHA (1:2 
ratio) on a representative panel of cancer cell lineages and the non tumoral MC3T3 mouse osteoblastic cell 
line (GI50 [µM], 72 h, MTT assay).[a] 
 
 A549 
Lung 
U-2 OS 
Bone 
MCF-7 
Breast 
T24 
Bladder 
LAMA 
CML 
HL-60 
AML 
HepG2 
Liver 
MC3T3 
Bone 
2a 0.115 0.122 0.089 0.175 0.079 0.017 2.43 1.62 
Auranofin 4.41 0.474 1.39 1.10 0.809 0.951 3.62 1.39 
DHA 11.1 4.10 9.67 4.99 5.60 3.25 12.0 3.55 
3 1.16 2.51 0.380 0.191 0.662 0.500 5.23 17.9 
3 / DHA (1:2) 1.99 1.25 0.610 0.319 0.800 0.471 4.71 1.76 
 
[a] The GI50 values represent the concentration of compound causing 50% inhibition of cell growth.  
Mean of at least three independent experiments. 
 
As in the case of PC-3 cells the GI50 values for six cancer cell lines were in the lower 
nM range spanning from 79 to 175 nM. Overall, complex 2a exhibited a much stronger 
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potency than auranofin (15-fold), DHA (60-fold), complex 3 (9-fold) and the mixture of 3 
and DHA (10-fold) in the representative prostate, lung, bone, breast, bladder and leukemia 
cells. Of note, 2a was 13.3 times more selective towards U-2 OS bone cancer cells than 
MC3T3 normal bone cells, much higher than auranofin (2.9-fold), whereas DHA did not 
express any selectivity. The efficacy of complex 2a was confirmed using a clonogenic assay 
(or colony formation assay), an in vitro cell survival assay based on the ability of a single cell 
to form a colony (>50 cells), and a method of choice to determine the effectiveness of 
radiotherapy or cytotoxic agents 19. At concentrations above 100 nM, no visible colony of 
PC-3 prostate or T24 bladder cells could be observed, indicating the ability of low 
concentrations complex 2a to completely abolish the capacity of these cells to proliferate 
(Suppl. Fig 1). 
Overall, these results show that hybrid complex 2a is extensively more effective than 
the control molecules used in this study on all the tested cancer cell line models, even on 
hepatocellular carcinoma HepG2, a cancer model notoriously known to be difficult to treat 
by chemotherapy 20, suggesting that gold(I)-artemisinin like hybrid complexes could 
represent potential novel anticancer drugs. 
 
High reactive oxygen species (ROS) levels are harmful to cells, and oxidative stress 
can have a tumor-suppressive effect 21. ROS levels were increased after treatment with 
auranofin or complex 2a, and a weaker effect on ROS formation was noted for DHA in some 
cell lines (Suppl. Fig 2). In general, no significant differences in the amount of generated 
ROS were observed across cell lines and treatments, suggesting that the amount of ROS 
produced could not explain the differential anti-tumor efficacies among treatments. The 
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behavior of cell lines to ROS-mediated cell death is strongly dependent on antioxidant 
enzymes or oxidative stress regulators. In this respect, the NRF2 antioxidant response 
pathway plays a fundamental role to protect our body against drug toxicity and stress-
induced diseases, by notably regulating the basal and inducible expression of detoxification 
and antioxidant enzymes 22. Although NRF2 activation is normally beneficial for health, 
persistent NRF2 activation has undesirable effects in cancer, promoting malignant 
progression by conferring chemo-and radioresistance, as well as promoting metabolic 
reprogramming 22. To quantify NRF2 antioxidant response activity, we relied on an ARE 
Reporter ² HepG2 liver cancer cell model containing a firefly luciferase gene under the 
control of a stably integrated ARE (antioxidant response element). Tert-butylhydroquinone 
or tBHQ was used to validate the response to stimulation of the ARE Reporter ² HepG2 cell 
line (Fig 2a). Both auranofin and DHA (and its bioactive derivatives) have been extensively 
reported to stimulate NRF2 transcriptional activity in various physio(patho)logical 
conditions including in cancer 23, 24, 25, 26, 27. Indeed, the treatment with auranofin (Fig 2b) or 
DHA (Fig 2c) markedly increased NRF2 transcriptional activity. To the best of our 
knowledge ARE activity monitoring has never been reported with cationic bisNHC gold(I) 
complexes such as complex 3. In contrast to auranofin and DHA, complex 3 treatment was 
associated with a stimulation of ARE activity mostly significant beyond 1 µM (Fig 2d). 
Unexpectedly, owing to the fact that both DHA and complex 3 stimulated ARE activity in 
HepG2 cell line, the hybrid complex 2a did not stimulate ARE activity. Instead, the 
treatment with complex 2a was associated with a remarkable dose-dependent inhibition of 
NRF2 transcriptional activity starting as low as 10 nM dose (Fig 2e), and a calculated IC50 of 
850 nM. To substantiate this finding, we also monitored NRF2 transcriptional activity, by 
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using an inducible ARE Reporter containing a renilla luciferase gene in a second model, the 
MCF7 breast cancer cells. As shown in Fig 2f, complex 2a was again able to inhibit NRF2 
transcriptional activity induced by 10 µM of tBHQ (calculated IC50 of 1.14 µM) whereas 
neither auranofin, DHA nor complex 3 were capable of suppressing tBHQ-induced NRF2 
activity (data not shown). 
Figure 2. Complex 2a inhibits NRF2 transcriptional activity.  
a-e, NRF2 transcriptional activity was evaluated in HepG2 cancer cell model treated with tBHQ, auranofin, 
DHA, 3 and 2a compounds. The ARE Reporter – HepG2 cell line contains a firefly luciferase gene under the 
control of ARE stably integrated into HepG2 cells. This cell line is validated for the response to the 
stimulation of tert-butylhydroquinone (tBHQ). f, the inhibitory effect of complex 2a was evaluated in NRF2 
ARE – Responsive Renilla Reporter MCF-7 human breast cancer, stimulated by 10 µM tBHQ for 7h. 
Mean of at least three independent experiments ± SD. 
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Interestingly, NRF2 directly regulates the ATP-binding cassette (ABC) superfamily 
multidrug efflux pumps expression in a number of human tumors 28. Overexpression of 
such multidrug-resistance-associated proteins including MRP1 or MDR1 is recognized as a 
major impediment to successful chemotherapies in vitro and in vivo 29. To further 
substantiate a role for complex 2a as a potential anticancer drug, we evaluated its efficacy 
towards multidrug-resistant HL-60 acute myeloid leukemia cells 30, grown in medium 
supplemented with increasing concentrations of doxorubicin or etoposide, causing the 
overexpression of MRP1 or MDR1, respectively 31. Contrary to parental HL-60 cells (Fig 3a), 
both doxorubicin and etoposide failed to trigger cell death in chemoresistant HL-60/Doxo 
(Fig 3b) and HL-60/VP16 cells (Fig 3c). Noteworthy, complex 2a could overcome resistance 
to doxorubicin and etoposide in both HL-60/Doxo (Fig 3b) and HL-60/VP16 cells (Fig 3c), 
with GI50 values similar to the one calculated for the chemosensitive parental HL-60 cells. In 
line with previous reports showing that NRF2 genetic silencing could restore 
chemosensitivity through a significant downregulation of NRF2-targeted ATP-binding 
cassette (ABC) efflux transporters, our data suggest that complex 2a could overcome 
multidrug-associated chemoresistance. 
  
  13 
Figure 3. Complex 2a overcomes chemoresistance in HL-60 acute myeloid leukemia. 
Parental HL-60 cells (a), HL-60/Doxo (b) and HL-60/VP16 (c) were incubated in the absence or presence of 
1 mM doxorubicin or 5mM etoposide (VP16) or with increasing concentration of complex 2a for 72h.  
(GI50 [µM], 72 h, MTT assay).[a] Mean of at least three independent experiments ± SD. 
 
 
We next attempted to study the potential chemosensitizing effects of complex 2a 
particularly in liver cancer, where the multiple kinase inhibitor sorafenib is the first-line 
systemic therapy since 2007. Yet, sorafenib has been shown to provide limited survival 
benefits, suggesting the existence of primary and acquired drug resistance mechanisms, and 
several lines of evidence suggest a key role for NRF2 signaling. First, somatic mutations of 
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NRF2 and Keap1 ³ the repressor protein that binds to NRF2 and promotes its degradation 
by the ubiquitin proteasome pathway ³ have been documented in hepatocarcinoma 32. 
Second, exome analyses have shown that NRF2 is a driver gene for liver carcinogenesis 33. 
Third, sorafenib itself can augment both mRNA and protein levels of NRF2 in 
hepatocarcinoma 34, 35. In that regard, Sun and co-workers recently demonstrated that 
shRNA strategy against NRF2 was able to significantly enhance the anticancer activity of 
sorafenib in hepatocarcinoma cell and animal models 34. Accordingly, we hypothesized that 
the NRF2 inhibitory effect of complex 2a could sensitize to sorafenib in HepG2 cells. The 
treatment of HepG2 cells with sorafenib was indeed associated with a significant increase 
in NRF2 transcriptional activity (Fig 4a). As anticipated, complex 2a remarkably reversed 
the NRF2 transcriptional activity surge induced sorafenib, starting as low as 10 nM dose, 
with a calculated IC50 of 511 nM (Fig 4b). To establish the proof-of-concept that complex 2a 
could therefore serve as a sensitizing agent for sorafenib in hepatocarcinoma, we relied on 
an isobologram analysis 36. Complex 2a displayed a GI50 value of 2.4 µM toward HepG2 
(Table 2) whereas the GI50 of sorafenib value was achieved at 4.1 µM (data not shown). We 
exposed HepG2 cells to fixed doses of sorafenib (1 and 2.5 µM) in combination with several 
doses of complex 2a ranging from 1 nM to 1 µM, or to fixed doses of complex 2a (500 nM 
and 1 µM) combined with 10 nM to 5 µM sorafenib (Fig 4c).  
In all tested combinations, the synergy of effect was remarkable with calculated 
combination indexes (CI) significantly below the value of 1 that represents an additive effect 
(Fig 4c). Of note, as shown by the CI values (Fig 4c) and the isoboles (Fig 4d), a better 
synergism was observed with fixed concentration complex 2a clearly indicating that 
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inhibition of NRF2 activity by complex 2a counteracts a mechanism of resistance hereby 
sensitizing hepatocarcinoma cells to sorafenib. 
Figure 4. Complex 2a sensitizes to sorafenib in HepG2 cells through inhibition of NRF2 activity.  
a, NRF2 transcriptional activity was evaluated in HepG2 cancer cell model treated with 1 µM of sorafenib for 
7h. The ARE Reporter – HepG2 cell line contains a firefly luciferase gene under the control of ARE stably 
integrated into HepG2 cells. 
b, the inhibitory effect of 2a compound was evaluated ARE Reporter – HepG2 cell line treated with 1 µM of 
sorafenib for 7h. 
c, Combination Index (CI) of 2a and sorefenib on HepG2 liver cancer cells (GI50 [µM], 72 h, MTT assay). 
d, Isobologram for GI50 values in which the dose of 2a alone is 2.43 µM and Sorafenib alone is 4.11 µM. The 
straight line connecting these intercept points (additivity line) is the locus of all dose pairs that, based on 
these potencies, should give the same effect. All tested dose pairs attain this effect with lesser quantities and 
are superadditive or synergistic. 
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Besides NRF2, two other major transcription factors have been reported to be 
modulated by arteminsin (and derivatives) or gold-containing drugs, namely NF-NB and 
Hypoxia Inducible Factor (HIF). The NF-NB signaling cascade mediates pleiotropic 
functions in the innate and adaptive immune responses. Beyond inflammation, the NF-ǋB 
pathway is also involved extensively in cancer development and progression 37, 38, 39. We 
made use of a A549 lung cancer cell model in which NF-ǋB lXcifeUaVe UeSRUWeU cRQVWUXcW iV 
stably integrated to quantify NF-NB activity. Stimulation of NF-NB was conducted with the 
TNFD cytokine, and peaked after 7 hours of treatment (Suppl. Fig 3a). Auranofin has been 
previously reported to inhibit NF-NB activation regardless of the nature of the stimulus 
(TNFD, IL-1E, LPS) in various cell systems, including cancer 40, 41, 42. A wealth of reports also 
establish that artemisinin derivatives inhibit NF-ǋB acWiYaWiRQ iQ numerous solid cancer and 
hematological cell lineages 43, 44, 45, 46. Both auranofin and DHA inhibited NF-NB activity 
triggered by TNFD (Suppl. Fig 3b) with IC50 values reminiscent of their capability to inhibit 
cell proliferation (Table 2). As shown in Suppl. Fig 3b, complex 2a remarkably suppressed 
NF-NB activity at very low concentrations (IC50 = 627 nM). The inhibitory effect of complex 
2a might be related to the cationic bisNHC gold(I) moiety, also present in complex 3, which 
exhibited similar efficacy towards NF-NB activity (IC50 = 664 nM, Suppl. Fig 3b). Hypoxia, 
the decrease in the physiological level of tissue oxygen, is a hallmark of solid tumors, and 
the adjustment of tumor cells to the lack of oxygen is critical for the development of 
aggressive tumor phenotype 47 and associated with treatment resistance and poor clinical 
prognosis 48. Recent studies have shown that auranofin could sensitize hypoxic tumor cells 
to irradiation 49, and inhibits NF-NB activation induced by hypoxia 42. A single direct 
evidence recently showed that auranofin could inhibit the accumulation of HIF-1ǂ, the 
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master transcription factor that regulates response to hypoxia 50. The HRE-Luc Reporter Cell 
Line-HeLa stably expressing luciferase reporter gene under the control of the hypoxia 
response element (HRE) was employed to study the hypoxia signaling pathway. In line with 
the aforementioned studies, HRE-mediated transcription was remarkably decreased by 
auranofin treatment in HeLa cells (Suppl. Fig 3c) with an IC50 of 745 nM. DHA also inhibited 
HIF activity to a lesser extent similar to its effect on NF-ǋB acWiYiW\ (IC50 > 10 µM). This is in 
line with a number of studies establishing the anti-hypoxic and subsequent anti-
angiogenesis effects of artemisinin and derivatives in cancer cells 51, 52, 53. The effect of 
cationic bisNHC gold(I) on HIF activity has never been reported prior this study. As shown 
in Suppl. Fig 3c, complex 3 also inhibited HIF activity (IC50 = 2.0 µM). In keeping with its 
remarkable effect on NRF2 and NF-ǋB transcriptional activities, complex 2a strongly 
impeded HRE-mediated transcription under hypoxia in HeLa cells with and IC50 of 942 nM 
(Suppl. Fig 3c). 
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Conclusion 
Herein, we report the synthesis, cytotoxicity, selectivity and the biological 
mechanistical aspects of cationic bisNHC gold(I) complexes incorporating an ether 
derivative of dihydroartemisinin (DHA, semi-synthetic derivative of artemisinin and 
metabolite of all artemisinin compounds) as building block. Hybride-complex 2a displayed 
a remarkable efficacy in killing a broad range of tumor cell models including solid tumors 
(prostate, bladder, bone, lung, breast, liver) and hematological tumors (CML, AML). The 
average GI50 was below 100 nM (17 to 175 nM range) for all cancer cell models except for 
the hepatocarcinoma HepG2 cells (GI50 = 2.43 µM), a model notoriously known to be 
refractory to chemotherapy. It should be indeed pointed out that the multikinase inhibitor 
sorafenib, the standard of care for hepatocarcinoma, displayed an GI50 value > 4.1 µM on 
the HepG2 cell line. Importantly, for all tested cancer cell models, complex 2a outperformed 
the drugs of reference used in this study, namely auranofin and DHA, both of which have 
been proposed for drug repurposing in cancer and are currently used in several phase I/II 
and phase II/III clinical trials (source: National Cancer Institute). Of note, complex 2a also 
presented a better specificity than auranofin and DHA for cancer cells vis-à-vis non cancer 
models (epithelial cells, osteoblasts and fibroblasts).  
Interestingly, complex 2a could overcome the multidrug resistance phenotype 
observed in malignant AML HL-60 cells exposed to anthracyclines (doxorubicin) or plant-
based alkaloids (etoposide), which remains a major obstacle to successful chemotherapy. 
The development of refractory disease in AML is frequently correlated with the expression 
of one or several multidrug resistance (MDR) genes, such as MDR1 or MRP1 54, which are 
notably target genes of the transcription factor NRF2 28 studied in this work.  
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Although complex 2a share some common features with auranofin or DHA 
regarding its impact on TrxR inhibition or ROS production, its mechanism of action appears 
quite distinctive. Similarly to auranofin or DHA, complex 2a could inhibit NF-ǋB aQd HIF 
(Hypoxia Inducible Factor) activities, yet in a steadily efficacy. With regard to NF-ǋB 
signaling, complex 2a surpassed the well-established effect of auranofin, which has been 
originally described as an anti-inflammatory drug (IC50 of 627 nM versus 2.97 µM in our cell 
model). Interestingly, one can speculate that the effect of complex 2a is likely related to its 
NHC scaffold of a bisNHC gold(I) complex, as complex 3 (IC50 of 664 nM). The efficacy of 
complex 2a could give support for its investigation as a potential drug in inflammation-
related pathological conditions. Complex 2a strongly inhibited the transcriptional activity 
of HIF (Hypoxia Inducing Factor) with an IC50 value close to that of auranofin, suggesting 
a possible mutual mechanism of action that could be related to Au(I) rather than the NHC 
scaffold since complex 3 was less active in inhibiting HIF transcriptional activity. The 
literature about the effect of auranofin on hypoxia is scarce and mostly indirect, and nothing 
is known about the effect of NHC gold(I) complexes on HIF signaling. Certainly, the data 
presented in this work demonstrate that the impact of gold(I) related compounds is 
presumably underestimated in pathologies associated with hypoxia.  
While auranofin, DHA or the NHC scaffold of a bisNHC gold(I) stimulated NRF2 
activity, complex 2a remarkably impeded NRF2 activity in two different cellular models 
(liver and lung), with an inhibitory effect seen at all tested concentrations as low as nM 
concentrations. The mechanism(s) of action of our complex 2a towards NRF2 signaling is 
unknown and will be investigated in details in future studies. If NRF2 is normally beneficial, 
cancer cells can support their malignant progression through various mechanisms leading 
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to its constitutive activation. These mechanisms leading to NRF2 activation include somatic 
mutations of KEAP1 and NRF2 genes, aberrant activation of the p62/SQSTM1, epigenetic 
silencing of the KEAP1 and CUL3 genes and oncogene-mediated transcriptional 
upregulation of the NRF2 gene 22, 55. Overall, cancer cells expressing high levels of NRF2 can 
undergo metabolic reprogramming 56 that drives aggressiveness and resistance to 
anticancer therapies, with tumors more difficult to manage clinically 22, 55.  
The elevated activity of NRF2 in cancer cells has been shown to decreased the 
sensitivity to ionizing radiations and common chemotherapies. In this regard, 
hepatocarcinoma is an ideal example as KEAP1/NRF2 has been shown to be one of the most 
frequently mutated pathways in this tumor location 57. Our data reveal that complex 2a 
dramatically sensitizes to sorafenib in the HepG2 liver cells, where aberrant NRF2 activity 
is further amplified by sorafenib. There was a stunning synergy of effect when complex 2a 
was combined to sorafenib, certainly indicating that inhibition of NRF2 activity by complex 
2a counteracts this mechanism of resistance hereby sensitizing hepatocarcinoma cells to 
sorafenib. Our data potentially sheds light on complex 2a as a potential sorafenib sensitizing 
agent to allow more effective therapeutic regimens designed for hepatocarcinoma patients. 
The inhibition of NRF2 signaling is therefore highly desirable in cancer to improve the 
efficacy of the treatments. Brusatol, a component of the Brucea javanica plant, has been 
identified as a potential inhibitor of NRF2 by enhancing its ubiquitination, and enhancing 
efficacy of chemotherapy in lung cancer models 58. However, brusatol is not specific to NRF2 
and is more a global protein synthesis inhibitor 59. The search for inhibitors of a transcription 
factor such as NRF2 remains a major challenge in pharmacology as transcription factors are 
W\Sicall\ cRQVideUed ´XQdUXggableµ 60.  
  22 
The mechanism(s) by which complex 2a inhibits three majors NF-NB, HIF and NRF2 
transcriptional activities involved in cancer progression and resistance warrants further 
investigation. A better appreciation of its mechanism(s) of action, notably its unique effect 
towards NRF2, is needed before we can fully determine its therapeutic value in preclinical 
models. 
 
Methods 
All experimental methods used for the herein described studies are available as Supporting 
Information. 
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Experimental section 
Chemistry 
1. General information 
All complexation reactions were performed under an inert atmosphere of dry nitrogen by 
using standard vacuum line and Schlenk tube techniques. Reactions involving silver 
compounds were performed with the exclusion of light. CH3CN was dried over CaH2 and 
subsequently distilled. 10ȕ-(20-Bromopropoxy)dihydroartemisinin (DHA-C3) was synthetized 
according a modified literature procedure 1. All other reagents were used as received from 
commercial suppliers. 1H (300 or 400 MHz) and 13C NMR spectra (75 or 101 MHz) and 2D 
experiments were recorded at 298 K on Bruker AV300, Bruker AV400 or Bruker Avance 500 
spectrometers in CDCl3 as solvent. All chemical shifts for 1H and 13C are relative to TMS using 
1H (residual) or 13C chemical shifts of the solvent as a secondary standard. All the 1H and 13C 
signals were assigned based on chemical shifts, spin-spin coupling constants, splitting patterns 
and signal intensities, and by using 1H-1H COSY45, 1H-13C HMBC and 1H-13C HSQC/HMQC, 
experiments for complexes 2a-2c. Gradient-enhanced 1H COSY45 was realised included 2 
scans for per increment. 1H-13C correlation spectra using a gradient-enhanced HSQC/HMQC 
sequence (delay was optimised for 1JCH of 145 Hz) was obtained with 2 scans per increment. 
Gradient-enhanced HMBC experiment was performed allowing 62.5 ms for long-range 
coupling evolution (8 scans were accumulated). Typically, 1024 t2 data points were collected 
for 256 t1 increments. High Resolution Mass Spectrometry (HRMS) analysis were performed 
with a Xévo G2 QTOF Waters spectrometer using electrospray ionization (ESI) by the "Service 
de Spectrométrie de Masse de Chimie UPS-CNRS (Toulouse)". Elemental analyses were 
carried out by the ³Service de Microanalyse du Laboratoire de Chimie de Coordination 
(Toulouse)´. The absorbance for MTT assay was measured using a Promega E7031 microplate 
reader. 
 
2. Synthesis of proligands 1a-c and complexes 2a-c 
2.1. Synthesis of proligands 1a-c 
The following picture describes the numbering of H (1H NMR) and C (13C NMR). These 
notations are used in the following experimental section. 
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10β-(20-Bromopropoxy)dihydroartemisinin (DHA-C3)[1] 
Under a nitrogen atmosphere, dihydroartemisinin (DHA) (2 g, 7.0 mmol) was dissolved in 
200 mL Et2O. 3-Bromopropan-1-ol (0.76 mL, 8.4 mmol, 1.2 eq.) and BF3.Et2O (6 drops) were 
added and the reaction mixture was stirred for 4 h at room temperature. Then the solution was 
treated with a saturated solution of NaHCO3 and the product was extracted with Et2O (3 x 20 
mL). The combined organic phases were dried over Na2CO3, filtered and the solvent was 
evaporated to dryness. The crude product was purified by column chromatography on silica 
using hexane-ethyl acetate as eluent (100/0 to 100/20) to give a white solid (1.277 g, 45 % 
yield). 1H NMR (400 MHz, CDCl3): δ = 5.44 (s, 1H, H12), 4.82 (d, J = 3.4 Hz, 1H, H10), 4.04-
3.97 (m, 1H, H18), 3.54-3.47 (m, 3H, H18, H20), 2.70-2.60 (m, 1H, H9), 2.43-2.33 (m, 1H, 
H4), 2.15-2.06 (m, 2H, H19), 2.03-2.01 (m, 1H, H4), 1.94-1.85 (m, 1H, H5), 1.80-1.72 (m, 2H, 
H8), 1.68-1.62 (m, 1H, H7), 1.54-1.50 (m, 1H, H8a), 1.49-1.47 (m, 1H, H5), 1.46 (s, 3H, H14), 
1.37-1.30 (m, 1H, H6), 1.29-1.23 (m, 1H, H5a), 0.97 (d, J = 6.3 Hz, 3H, H15), 0.94-0.89 (m, 
1H, H7), 0.92 (d, J = 7.4 Hz, 3H, H16). 13C NMR (75 MHz, CDCl3): δ = 104.05 (1C, C3), 
102.07 (1C, C10), 87.89 (1C, C12), 80.99 (1C, C12a), 65.66 (1C, C18), 52.56 (1C, C5a), 44.36 
(1C, C8a), 37.42 (1C, C6), 36.40 (1C, C4), 34.62 (1C, C7), 32.52 (1C, C19), 30.86 (1C, C9), 
30.57 (1C, C20), 26.16 (1C, C14), 24.65-24.49 (2C, C5, C8), 20.35 (1C, C15), 12.96 (1C, C16). 
 
10β-(21-Bromobutoxy)dihydroartemisinin (DHA-C4) 
Under a nitrogen atmosphere, dihydroartemisinin (DHA, 500 mg, 1.76 mmol) was dissolved 
in 200 mL Et2O. 4-Bromobutan-1-ol (398 mg, 2.6 mmol, 1.48 eq.) and BF3.Et2O (6 drops) were 
added and the reaction mixture was stirred for 4 h at room temperature. Then the solution was 
treated with a saturated solution of NaHCO3 and the product was extracted with Et2O (3 x 20 
S5 
 
 
mL). The combined organic phases were dried over Na2CO3, filtered and the solvent was 
evaporated to dryness. The crude product was purified by column chromatography on silica 
using hexane-ethyl acetate as eluent (100/0 to 100/20) to give a white solid (220.3 mg, 29 % 
yield). Anal. Calcd. for C19H31BrO5: C, 54.42; H, 7.45. Found: C, 54.36; H, 7.38. 1H NMR (400 
MHz, CDCl3): δ = 5.40 (s, 1H, H12), 4.80 (d, J = 3.2 Hz, 1H, H10), 3.9-3.88 (m, 1H, H18), 
3.50-3.36 (m, 3H, H18, H21), 2.71-2.59 (m, 1H, H9), 2.45-2.32 (m, 1H, H4), 2.08-2.03 (m, 1H, 
H4), 1.99-1.86 (m, 3H, H19, H5), 1.83-1.74 (m, 4H, H8, H20), 1.70-1.63 (m, 1H, H7), 1.56-
1.53 (m, 1H, H8a), 1.51-1.49 (m, 1H, H5), 1.46 (s, 3H, H14), 1.38-1.32 (m, 1H, H6), 1.30-1.26 
(m, 1H, H5a), 0.98 (d, J = 6.3 Hz, 3H, H15), 0.97-0.95 (m, 1H, H7), 0.92 (d, J = 7.4 Hz, 3H, 
H16). 13C NMR (101 MHz, CDCl3): δ = 104.10 (1C, C3), 102.02 (1C, C10), 87.92 (1C, C12), 
81.10 (1C, C12a), 67.44 (1C, C18), 52.58 (1C, C5a), 44.42 (1C, C8a), 37.49 (1C, C6), 36.44 
(1C, C4), 34.64 (1C, C7), 33.63 (1C, C21), 30.90 (1C, C9), 29.83 (1C, C19), 28.34 (1C, C20), 
26.22 (1C, C14), 24.69-24.51 (2C, C5, C8), 20.37 (1C, C15), 13.04 (1C, C16). HRMS (ES+): 
calcd. for C19H31BrNaO5 m/z = 441.1253; found 441.1251. 
 
10β-(22-Bromopentoxy)dihydroartemisinin (DHA-C5) 
Under a nitrogen atmosphere, dihydroartemisinin (DHA, 1 g, 3.5 mmol) was dissolved in 
200 mL Et2O. 5-Bromopentan-1-ol (601 mg, 3.6 mmol, 1.03 eq.) and BF3.Et2O (6 drops) were 
added and the reaction mixture was stirred for 4 h at room temperature. Then the solution was 
treated with a saturated solution of NaHCO3 and the product was extracted with Et2O (3 x 20 
mL). The combined organic phases were dried over Na2CO3, filtered and the solvent was 
evaporated to dryness. The crude product was purified by column chromatography on silica 
using hexane-ethyl acetate as eluent (100/0 to 100/20) to give a white solid (314.4 mg, 21 % 
yield). Anal. Calcd. for C20H33BrO5: C, 55.43; H, 7.68. Found: C, 55.49; H, 7.82. 1H NMR (400 
MHz, CDCl3): δ = 5.41 (s, 1H, H12), 4.79 (d, J = 3.2 Hz, 1H, H10), 3.87 (dt, J = 9.8, 6.2 Hz, 
1H, H18), 3.45-3.37 (m, 3H, H18, H22), 2.66-2.61 (m, 1H, H9), 2.39 (ddd, J = 14.5, 13.4, 3.9 
Hz, 1H, H4), 2.08-2.02 (m, 1H, H4), 1.94-1.87 (3H, H5, H21), 1.82-1.77 (m, 1H, H7), 1.67-
1.48 (m, 8H, H5, H8, H8a, H19, H20), 1.50 (s, 3H, H14), 1.40-1.32 (m, 1H, H6), 1.29-1.22 (m, 
1H, H5a), 0.97 (d, J = 6.3 Hz, 3H, H15), 0.98-0.91 (m, 1H, H7), 0.92 (d, J = 7.4 Hz, 3H, H16). 
13C NMR (101 MHz, CDCl3): δ = 104.05 (1C, C3), 101.99 (1C, C10), 87.92 (1C, C12), 81.12 
(1C, C12a), 68.01 (1C, C18), 52.58 (1C, C5a), 44.45 (1C, C8a), 37.46 (1C, C6), 36.44 (1C, 
C4), 34.66 (1C, C7), 33.81 (1C, C22), 32.41 (1C, C21), 30.92 (1C, C9), 28.82 (1C, C19), 26.21 
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(1C, C14), 24.96 (1C, C20), 24.68-24.48 (2C, C5, C8), 20.36 (1C, C15), 13.04 (1C, C16). 
HRMS (ES+): calcd. for C20H33BrNaO5 m/z = 455.1409; found 455.1409. 
 
 
3’-methyl-1’-[10β-(20-propoxy)dihydroartemisinin]1H-imidazol-3-ium bromide (1a) 
To a stirred solution of DHA-C3 (304 mg, 0.75 mmol) in CH3CN (6 mL) under reflux, 1-
methylimidazole (60 PL, 0.75 mmol) was added and the reaction mixture was stirred 3 days 
under reflux. The solvent was evaporated under reduced pressure and the viscous residue was 
purified by chromatography on silica with CH2Cl2-MeOH as eluent (1/0.1 to 1/0.25) to afford 
a white solid (238 mg, 65% yield). Anal. Calcd. for C22H35BrN2O5: C, 54.21; H, 7.24; N, 5.75. 
Found C, 54.12; H, 7.26; N, 5.68. 1H NMR (400 MHz, CDCl3): δ = 10.44 (s, 1H, H2¶), 7.48 (s, 
1H, H4¶), 7.38 (s, 1H, H5¶), 5.38 (s, 1H, H12), 4.79 (d, J = 3.6 Hz, 1H, H10), 4.44 (t, J = 7.2 
Hz, 2H, H20), 4.14 (s, 3H, H6¶), 3.92-3.86 (m, 1H, H18), 3.53-3.47 (m, 1H, H18), 2.68-2.61 
(m, 1H, H9), 2.37 (ddd, J = 14.6, 13.4, 4.0 Hz, 1H, H4), 2.29-2.22 (m, 2H, H19), 2.04 (ddd, J 
= 14.6, 4.9, 2.9 Hz, 1H, H4), 1.93-1.86 (m, 1H, H5), 1.81-175 (m, 1H, H7), 1.72-1.61 (m, 2H, 
H8), 1.51-1.44 (m, 2H, H5, H8a), 1.42 (s, 3H, H14), 1.38-1.31 (m, 1H, H6), 1.29-1.23 (m, 1H, 
H5a), 0.97 (d, J = 6.3 Hz, 3H, H15), 0.95-0.89 (m, 1H, H7), 0.92 (d, J = 7.4 Hz, 3H, H16). 13C 
NMR (101 MHz, CDCl3): δ = 137.90 (1C, C2¶), 123.37 (1C, C4¶), 122.15 (1C, C5¶),104.23 
(1C, C3), 102.20 (1C, C10), 87.96 (1C, C12), 80.92 (1C, C12a), 64.60 (1C, C18), 52.42 (1C, 
C5a), 47.48 (1C, C20), 44.16 (1C, C8a), 37.45 (1C, C6¶), 36.90 (1C, C6), 36.33 (1C, C4), 34.45 
(1C, C7), 30.77 (1C, C9), 30.60 (1C, C19), 26.10 (1C, C14), 24.63-24.57 (2C, C5, C8), 20.29 
(1C, C15), 13.13 (1C, C16). HRMS (ES+): calcd. for C22H35N2O5 m/z = 407.2545; found 
407.2546. 
 
3’-methyl-1’-[10β-(21-butoxy)dihydroartemisinin]1H-imidazol-3-ium bromide (1b) 
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To a stirred solution of DHA-C4 (75 mg, 0.18 mmol) in CH3CN (3 mL) under reflux, 1-
methylimidazole (57 PL, 0.72 mmol, 4 eq.) was added and the reaction mixture was stirred 5 
days under reflux. The solvent was evaporated under reduced pressure and the viscous residue 
was purified by chromatography on silica with CH2Cl2-MeOH as eluent (1/0.1 to 1/0.25) to 
afford a white solid (83 mg, 92% yield). Anal. Calcd. for C23H37BrN2O5: C, 55.09; H, 7.44; N, 
5.59. Found C, 55.12; H, 7.56; N, 5.58. 1H NMR (400 MHz, CDCl3): δ = 10.38 (s, 1H, H2¶), 
7.55 (t, 1H, J = 1.8 Hz, H4¶), 7.42 (t, 1H, J = 1.8 Hz, H5¶), 5.34 (s, 1H, H12), 4.75 (d, J = 3.4 
Hz, 1H, H10), 4.37 (t, J = 7.4 Hz, 2H, H21), 4.10 (s, 3H, H6¶), 3.83 (dt, 1H, J = 9.9, 6.0 Hz, 
H18), 3.40 (dt, 1H, J = 9.9, 6.4 Hz, H18), 2.62-2.52 (m, 1H, H9), 2.37-2.29 (m, 1H, H4), 2.04-
1.83 (m, 3H, H4, H20), 1.90-1.83 (m, 1H, H5), 1.73-1.59 (m, 5H, H7, H8, H19), 1.51-1.41 (m, 
2H, H8a, H5), 1.39 (s, 3H, H14), 1.35-1.27 (m, 1H, H6), 1.25-1.17 (m, 1H, H5a), 0.94 (d, J = 
6.3 Hz, 3H, H15), 0.91-0.83 (m, 1H, H7), 0.87 (d, J = 7.3 Hz, 3H, H16). 13C NMR (101 MHz, 
CDCl3): δ = 137.95 (1C, C2¶), 123.41 (1C, C4¶), 121.59 (1C, C5¶),104.13 (1C, C3), 102.12 
(1C, C10), 87.91 (1C, C12), 81.03 (1C, C12a), 67.43 (1C, C18), 52.49 (1C, C5a), 49.88 (1C, 
C21), 44.29 (1C, C8a), 37.43 (1C, C6¶), 36.82 (1C, C6), 36.38 (1C, C4), 34.51 (1C, C7), 30.84 
(1C, C9), 27.28-26.44 (2C, C19, C20), 26.17(1C, C14), 24.65-24.52 (2C, C5, C8), 20.32 (1C, 
C15), 13.09 (1C, C16). HRMS (ES+): calcd. for C23H37N2O5 m/z = 421.2702; found 421.2704. 
 
3’-methyl-1’-[10β-(22-pentoxy)dihydroartemisinin]1H-imidazol-3-ium bromide (1c) 
To a stirred solution of DHA-C5 (189 mg, 0.45 mmol) in CH3CN (6 mL) under reflux, 1-
methylimidazole (143 PL, 0.43 mmol, 4 eq.) was added and the reaction mixture was stirred 3 
days under reflux. The solvent was evaporated under reduced pressure and the viscous residue 
was purified by chromatography on silica with CH2Cl2-MeOH as eluent (1/0.1 to 1/0.25) to 
afford a white solid (91 mg, 39% yield). Anal. Calcd. for C24H39BrN2O5: C, 55.92; H, 7.63; N, 
5.43. Found C, 55.86; H, 7.56; N, 5.38. 1H NMR (400 MHz, CDCl3): δ = 10.40 (s, 1H, H2¶), 
7.54 (t, 1H, J = 1.8 Hz, H4¶), 7.43 (t, 1H, J = 1.8 Hz, H5¶), 5.34 (s, 1H, H12), 4.73 (d, J = 3.6 
Hz, 1H, H10), 4.33 (t, J = 7.5 Hz, 2H, H22), 4.12 (s, 3H, H6¶), 3.79 (dt, 1H, J = 9.8, 6.3 Hz, 
H18), 3.45 (dt, 1H, J = 9.8, 6.5 Hz, H18), 2.62-2.54 (m, 1H, H9), 2.38-2.30 (m, 1H, H4), 2.04-
1.92 (m, 3H, H4, H21), 1.89-1.83 (m, 1H, H5), 1.74-1.58 (m, 5H, H7, H8, H19), 1.53-1.37 (m, 
4H, H5, H8a, H20), 1.40 (s, 3H, H14), 1.35-1.29 (m, 1H, H6), 1.27-1.18 (m, 1H, H5a), 0.94 (d, 
J = 6.3 Hz, 3H, H15), 0.90-0.83 (m, 1H, H7), 0.86 (d, J = 7.3 Hz, 3H, H16). 13C NMR (101 
MHz, CDCl3): δ = 137.60 (1C, C2¶), 123.51 (1C, C4¶), 121.89 (1C, C5¶),104.07 (1C, C3), 
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101.99 (1C, C10), 87.88 (1C, C12), 81.09 (1C, C12a), 67.86 (1C, C18), 52.52 (1C, C5a), 50.00 
(1C, C22), 44.37 (1C, C8a), 37.44 (1C, C6¶), 36.77 (1C, C6), 36.40 (1C, C4), 34.56 (1C, C7), 
30.88 (1C, C9), 30.06-29.01 (2C, C19, C21), 26.19 (1C, C14), 24.66-24.48 (2C, C5, C8), 23.00 
(1C, C20), 20.35 (1C, C15), 13.05 (1C, C16). HRMS (ES+): calcd. for C24H39N2O5 m/z = 
435.2859; found 435.2861. 
 
2.2. Synthesis of complexes 2a-c 
Complex 2a 
In a schlenk tube, 1a (102 mg, 0.21 mmol) and Ag2O (25 mg, 0.11 mmol) were dissolved in 
CH3CN (3 mL) under a nitrogen atmosphere and protection of the light and stirred overnight at 
room temperature. A solution of AgNO3 (19 mg, 0.11 mmol) in 2 mL of CH3CN was added 
and the mixture was stirred for 2 h. Finally, Au(SMe2)Cl (32 mg, 0.11 mmol) was added and 
after stirring for 1 h at room temperature, the solution was filtered through a pad of celite and 
the solvent removed under reduced pressure to afford a white solid (95 mg, 84% yield). Crystals 
suitable for X-ray diffraction analysis were obtained by slow diffusion of Et2O in a CH3CN 
solution of this complex. Anal. Calcd. For C44H68AuN5O13: C, 49.30; H, 6.39; N, 6.53. Found 
C, 49.32; H, 6.45; N, 5.49. 1H NMR (400 MHz, CDCl3): δ 7.26 (d, J = 1.8 H], 1H, H4¶), 7.16 
(d, J = 1.9 H], 1H, H5¶), 5.37 (s, 1H, H12), 4.79 (d, J = 3.5 Hz, 1H, H10), 4.28 (t, J = 7.0 Hz, 
2H, H20), 3.95 (s, 3H, H6¶), 3.91-3.89 (m, 1H, H18), 3.46-3.43 (m, 1H, H18), 2.64-2.62 (m, 
1H, H9), 2.37-2.34 (m, 1H, H4), 2.19-2.16 (m, 2H, H19), 2.04-2.02 (m, 1H, H4), 1.89-1.87 (m, 
1H, H5), 1.73-1.71 (m, 2H, H8), 1.61-1.59 (m, 1H, H7), 1.48-1.46 (m, 1H, H8a), 1.46-1.43 (m, 
1H, H5), 1.42 (s, 3H, H14), 1.32-1.30 (m, 1H, H6), 1.25-1.20 (m, 1H, H5a), 0.96 (d, J = 6.2 
Hz, 3H, H15), 0.95-0.92 (m, 1H, H7), 0.91 (d, J = 7.4 Hz, 3H, H16). 13C NMR (101 MHz, 
CDCl3): δ 183.71 (1C, C2¶), 123.26 (1C, C4¶), 121.84 (1C, C5¶), 104.19 (1C, C3), 101.98 (1C, 
C10), 87.93 (1C, C12), 80.89 (1C, C12a), 64.81 (1C, C18), 52.46 (1C, C5a), 48.50 (1C, C20), 
44.22 (1C, C8a), 38.21 (1C, C6¶), 37.52 (1C, C6), 36.35 (1C, C4), 34.50 (1C, C7), 31.70 (1C, 
C19), 30.75 (1C, C9), 26.11 (1C, C14), 24.66-24.54 (2C, C5, C8), 20.31 (1C, C15), 13.10 (1C, 
C16) HRMS (ES+): calcd. for C44H68AuN4O10 m/z 1009.4601; found 1009.4591. 
 
Complex 2b 
Under a nitrogen atmosphere, potassium carbonate (27.7 mg, 0.20 mmol) was added to a 
mixture of 1b (80 mg, 0.16 mmol) and Au(SMe2)Cl (26.5 mg, 0.09 mmol) in dry CH3CN (5 
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mL). The mixture was then heated to 60 °C and stirred for 2 h. After cooling to room 
temperature, the solution was filtered through a pad of celite and the solvent removed under 
reduced pressure. The complex was purified by preparative chromatography on silica plate with 
CH2Cl2-MeOH as eluent (100/8) to afford a white solid (68.7 mg, 80% yield). Anal. Calcd. For 
C46H72AuClN4O10. C, 51.47; H, 6.76; N, 5.22. Found C, 51.39; H, 6.68; N, 5.18. 1H NMR (400 
MHz, CDCl3): δ 7.37 (d, J = 1.9 H], 1H, H4¶), 7.22 (d, J = 1.9 H], 1H, H5¶), 5.33 (s, 1H, H12), 
4.74 (d, J = 3.2 Hz, 1H, H10), 4.25 (t, J = 7.0 H], 2H, H21), 3.97 (s, 3H, H6¶), 3.86-3.80 (m, 
1H, H18), 3.42-3.37 (m, 1H, H18), 2.61-2.57 (m, 1H, H9), 2.38-2.30 (m, 1H, H4), 2.04-1.84 
(m, 4 H, H4, H5, H20), 1.76-1.58 (m, 5H, H7, H8, H19), 1.46-1.37 (m, 2H, H5, H8a), 1.40 (s, 
3H, H14), 1.30-1.19 (m, 2H, H5a, H6), 0.94 (d, J = 5.9 Hz, 3H, H15), 0.95-0.84 (m, 1H, H7), 
0.86 (d, J = 7.3 Hz, 3H, H16). 13C NMR (101 MHz, CDCl3): δ 183.57 (1C, C2¶), 123.45 (1C, 
C4¶), 121.53 (1C, C5¶), 104.10 (1C, C3), 101.99 (1C, C10), 87.87 (1C, C12), 80.97 (1C, C12a), 
67.50 (1C, C18), 52.40 (1C, C5a), 51.04 (1C, C21), 44.27 (1C, C8a), 38.42 (1C, C6¶), 37.49 
(1C, C6), 36.35 (1C, C4), 34.53 (1C, C7), 30.79 (1C, C9), 28.34 (1C, C20), 26.73, (1C, C19), 
26.16 (1C, C14), 24.65-24.48 (2C, C5, C8), 20.35 (1C, C15), 13.08 (1C, C16) HRMS (ES+): 
calcd. for C46H72AuN4O10 m/z 1037.4914; found 1037.4929. 
 
Complex 2c 
Under a nitrogen atmosphere, potassium carbonate (38.7 mg, 0.28 mmol) was added to a 
mixture of 1c (118.5 mg, 0.23 mmol) and Au(SMe2)Cl (35.3 mg, 0.12 mmol) in dry CH3CN (5 
mL). The mixture was then heated to 60 °C and stirred for 2 h. After cooling to room 
temperature, the solution was filtered through a pad of celite and the solvent removed under 
reduced pressure. The complex was purified by preparative chromatography on silica plate with 
CH2Cl2-MeOH as eluent (100/8) to afford a white solid (39.3 mg, 31% yield). Anal. Calcd. For 
C48H76AuClN4O10. C, 52.34; H, 6.95; N, 5.09. Found C, 52.39; H, 6.98; N, 5.08. 1H NMR (300 
MHz, CDCl3): δ 7.32 (d, J = 1.9 H], 1H, H4¶), 7.22 (d, J = 1.9 Hz, 1H, H5¶), 5.36 (s, 1H, H12), 
4.75 (d, J = 3.6 Hz, 1H, H10), 4.25 (t, J = 7.0 Hz, 2H, H22), 3.99 (s, 3H, H6¶), 3.88-3.78 (m, 
1H, H18), 3.41-3.33 (m, 1H, H18), 2.63-2.58 (m, 1H, H9), 2.43-2.32 (m, 1H, H4), 2.08-1.97 
(m, 4H, H4, H5, H21), 1.78-1.59 (m, 5H, H7, H8, H19), 1.53-1.38 (m, 7H, H5, H8a, H20), 1.43 
(s, 3H, H14), 1.30-1.24 (m, 2H, H5a, H6), 0.97 (d, J = 6.1 Hz, 3H, H15), 0.97-0.84 (m, 1H, 
H7), 0.87 (d, J = 7.4 Hz, 3H, H16). 13C NMR (101 MHz, CDCl3): δ 183.59 (1C, C2¶), 123.28 
(1C, C4¶), 121.65 (1C, C5¶), 104.08 (1C, C3), 101.91 (1C, C10), 87.86 (1C, C12), 81.01 (1C, 
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C12a), 67.85 (1C, C18), 52.49 (1C, C5a), 51.22 (1C, C22), 44.32 (1C, C8a), 38.38 (1C, C6¶), 
37.48 (1C, C6), 36.37 (1C, C4), 34.58 (1C, C7), 31.22 (1C, C21), 30.82 (1C, C9), 29.13 (1C, 
C19), 26.18 (1C, C14), 24.66-24.46 (2C, C5, C8), 23.23 (1C, C20), 20.37 (1C, C15), 13.02 
(1C, C16) HRMS (ES+): calcd. for C48H76AuN4O10 m/z 1065.5221; found 1065.5226. 
 
3. Crystallographic data for 2a 
All data were collected at low temperature using oil-coated shock-cooled crystals on a 
Bruker-AXS APEX II diffractometer with MoKa radiation (Ȝ = 0.71073 c). The structure was 
solved by direct methods 2 and all non hydrogen atoms were refined anisotropically using the 
least-squares method on F2 3. The absolute structure parameters have been refined using the 
Flack-method. CCDC-1978195 contain the additional crystallographic data. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif.  
Complex 2a: C44H68AuN5O13.12, Mr = 1074.0, crystal size = 0.40 x 0.30 x 0.05 mm3, 
orthorhombic, space group I222, a = 10.644(2) Å, b = 19.073(3) Å, c = 48.320(8) Å, V = 
9809(3) Å3, Z = 8, 59886 reflections collected, 6963 unique reflections (Rint = 0.1151), R1 = 
0.0568, wR2 = 0.1300 [I>2ı(I)], R1 = 0.1309, wR2 = 0.1727 (all data), absolute structure factor 
x = -0.021(8), residual electron density = 3.308 e Å-3. 
 
Biology 
1. Cell culture  
Cell lines were obtained from DSMZ (Braunschweig, Germany) or ATCC (Molsheim, 
France). Culture medium and antibiotics were from Lonza (Basel, Switzerland). Serum was 
from Perbio (Brebières, France).  
PC-3 human prostate cancer cells, and LAMA chronic myeloid leukemia were cultured in 
RPMI 1640 containing 10% fetal bovine serum (FBS) and 1% antibiotics (100 U/mL penicillin 
and 100 ȝg/mL streptomycin) at 37 C in 5% CO2 humidified incubators. HL-60 acute myeloid 
leukemia were cultured in RPMI 1640 containing 15% FBS and 1% antibiotics at 37 °C in 5% 
CO2 humidified incubators. HL-60/Doxo resistant cells (gift of Dr. JP. Marie, Hôtel Dieu, Paris, 
France) were grown in the same medium supplemented with 40 nM doxorubicin 4, 5. The 
selection of HL-60/VP16 cells was performed by stepwise increasing concentrations of 
etoposide, and cells were maintained continuously in the presence of 1 µM VP16. HepG2 
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human liver cancer cells were cultured in EMEM containing 10% FBS, 1% of nonessential 
amino acids, 1 mM of Na-pyruvate, 1% antibiotics and 600 µg/mL of Geneticin. MCF-7 human 
breast adenocarcinoma cells were cultured in Advanced MEM containing 10% FBS, 2 mM 
glutamine, 1% antibiotics and 2µg/mL of puromycin. A549 human lung carcinoma cells, T24 
human bladder carcinoma cells, U-2 OS human osteosarcoma and NIH3T3 murine fibroblast 
cells were cultured in DMEM medium containing 10% FBS and 1% antibiotics at 37 °C in 5% 
CO2 humidified incubators. MC3T3 mouse osteoblast cells were cultured in alpha-MEM 
medium containing 10% FBS and 1% antibiotics at 37 °C in 5% CO2 humidified incubators. 
RWPE-1 human prostate normal cells were cultured in K-SFM medium containing 0.05 mg/ml 
bovine pituitary extract (BPE) and 5 ng/ml epidermal growth factor (EGF) at 37 °C in 5% CO2 
humidified incubators. 
All experiments were started with low-passaged cells (<15 times). Hypoxia (0.1% O2, 5% 
CO2, 94.5% N2) was achieved using an In Vivo2 hypoxic workstation (Ruskinn, Bridgend, 
UK). 
 
2. Cell viability assay (MTT assay) 
The MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was used 
to determine cell death as originally described by Mosmann 6 and modified by Cuvillier et al. 
7. Briefly, cells were seeded 5,000 to 10,000 cells/well in 24-well plates depending on the cell 
type and allowed to attach overnight. All of the complexes were dissolved in DMSO. The 
concentration of the complexes was calculated according to the elemental composition of the 
complexes determined by the elemental analyses. Media in the presence of the tested complexes 
were added and serially diluted to various concentrations (from 5 ȝM to 0.01 ȝM). Next to these 
concentrations, for DHA 50, 20 and 10 ȝM and for the cationic bisNHC gold(I) complex 3 
0.001 ȝM have been used. The maximum concentration of DMSO in media did not exceed 0.5 
% (v/v). After 72 h of treatment, cells were incubated at 37 °C and 5% CO2 with 25 ȝL MTT 
solution (5 mg/mL; Sigma-Aldrich) in 24-well plates for approximately 3 to 4 h. After 
solubili]ation with 500 ȝL of lysis buffer (DMSO), forma]an was quantified by 
spectrophotometry with a microplate reader at 570 nm absorbance. The GI50 values 
corresponding to the concentration that caused 50% inhibition of cell proliferation were 
calculated from dose-response curves obtained by nonlinear regression analysis (Prism 8.3, 
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Graphpad Software, San Diego). All the results were calculated from data obtained in three 
independent experiments. 
 
3. Clonogenic assay 
PC-3 and T24 cells were counted and seeded (500 cells/well) to 6-well plates. Cells were 
allowed to attach overnight and then treated with different concentrations of complex 2a (0.01 
ȝM，0.1 ȝM, 0.25 ȝM, 0.5 ȝM, 1 ȝM, 5 ȝM). After incubation for additional 6 days for T24 
and 8 days for PC-3, the cells were washed with PBS (2 mL), fixed with methanol (1 mL) for 
20 min and stained with 0.5% crystal violet (2 mL) for 30 min. The relative survival was 
calculated from the number of single cells that formed colonies of more than 50 cells. 
 
4. Measurement of intracellular reactive oxygen species (ROS)  
The cellular ROS generation was shown by the increase of fluorescence intensity of DCF 
according to a previously reported protocol 8.  Briefly, PC-3, A549, MCF-7 and HepG2 cells 
were seeded at a density of 50,000 cells/well in 24-well plates for 24 h. Cells were washed with 
PBS buffer and stained with DCFH-DA (final concentration 20 ȝM) for 45 min. Then cells 
were washed with PBS buffer and the culture medium without phenol red containing gold 
complexes were added to the cells. The fluorescence intensity of DCF (excitation/emission, 
485/535 nm) was measured by fluorescence microplate reader at different time points. 
 
5. NRF2 transcriptional activity in MCF-7 and HepG2 cells 
The Hep G2 ± ARE-LucF, a stable cell line containing a firefly luciferase gene under the 
control of ARE (BPS Bioscience, Cat # 60513) was primarily used to monitor NRF2 
transcriptional activity. Cells were grown at 37qC with 5% CO2 using MEM medium 
supplemented with 10% FBS, 1% non-essential amino acids, 1 mM Na-pyruvate, 1% 
Penicillin/Streptomycin and 600 Pg/ml of Geneticin. Cells were harvested from culture in 
Growth Medium 1K and they were seeded at a concentration of 40,000 cells/well into white 
clear-bottom 96-well microplate in 45 ȝL of Growth Medium 1K without Geneticin. Cells were 
allowed to attach overnight and then treated with different concentrations of complex 2a (from 
0.01 ȝM to 20 ȝM), auranofin (from 0.01 ȝM to 20 ȝM) or DHA (from 0.01 ȝM to 3, 5, 10, 20 
and 50 ȝM), and complex 3 (from 0.01 ȝM to 20 ȝM). After incubation at 37 °C and 5% CO2 
for 16 hours, 100 ȝL ONE-Step luciferase assay reagent (BPS Bioscience Cat # 60690) was 
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added and rocked at room temperature for over 15 minutes. Then the luminescence of each well 
was determined by CLARIOstar microplate reader (BMG Labtech, Offenburg, Germany) to 
quantify induction of ARE. At least three independent experiments were performed as 
biological triplicates. 
The NRF2 Leeporter Renilla Reporter ± MCF7 cell line (Abeomics, Cat # 14-117ACL) 
was also used to monitor NRF2 transcriptional activity upon stimulation with tBHQ. Cells were 
grown at 37qC with 5% CO2 using Advanced Minimum Essential Medium supplemented with 
10% FBS, 2 mM glutamine and 1% Penicillin/Streptomycin, plus 2 ȝg/ml of Puromycin. Cells 
were seeded at a concentration of 5,000 cells/well into white clear-bottom 96-well microplate, 
and allowed to attach overnight. The next day, cells were stimulated with 10 µM tBHQ in 
presence or not of complex 2a (from 0.01 ȝM to 20 ȝM), auranofin (from 0.01 ȝM to 20 ȝM) 
or DHA (from 0.01 ȝM to 3, 5, 10, 20 and 50 ȝM), and complex 3 (from 0.01 ȝM to 20 ȝM).  
After incubation at 37 °C and 5% CO2 for 7 hours, cells were washed with 100 µL of  DPBS 
and 20 µL of cell lysate was added to the wells of microplate for 15 min incubation,  and then 
rocked at room temperature for cell lysis to occur. 100 µL of Renilla luciferase assay reagent 
(Promega, Cat # E2810) per well were added, then the luminescence of each well was 
determined by CLARIOstar microplate reader (BMG Labtech, Offenburg, Germany) to 
quantify induction of NRF2. 
At least three independent experiments were performed as biological triplicates. 
 
6. NF-țB WUanVcUiSWional acWiYiW\ 
The NF-țB-luciferase ± A549 cell line was used for monitoring the activity of NF-țB 
transcription factor (BPS Bioscience Cat # 60625). The firefly luciferase gene is controlled by 
4 copies of NF-țB response element located upstream of the TATA promoter. Cells were grown 
in DMEM medium supplemented with 10% FBS 1% Penicillin/Streptomycin plus 1 mg/ml of 
Geneticin. Cells were seeded at a concentration of 10,000 cells/well into white clear-bottom 96-
well microplate, and allowed to attach overnight. The next day, cells were stimulated by 1 
ng/mL TNFĮ in presence of not of complex 2a (from 0.01 ȝM to 20 ȝM), auranofin (from 0.01 
ȝM to 20 ȝM) or DHA (from 0.01 ȝM to 3, 5, 10, 20 and 50 ȝM), and complex 3 (from 0.01 
ȝM to 20 ȝM). After incubation at 37 °C and 5% CO2 for 7 hours, 100 ȝL ONE-Step luciferase 
assay reagent (BPS Bioscience Cat # 60690) was added and rocked at room temperature for 
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over 15 minutes. Then the luminescence of each well was determined by CLARIOstar 
microplate reader (BMG Labtech, Offenburg, Germany) to quantify induction of NF-țB. 
 
7. HIF transcriptional activity 
HIF Responsive Luciferase Reporter human cervical cancer Hela cell, stably expressing HIF 
firefly luciferase reporter vector, was used to monitor the activity of HIF transcription factor 
line (Signosis Cat # SL-0023). Cells were grown in DMEM medium  supplemented with 10% 
FBS 1% Penicillin/Streptomycin plus 100 µg/ml of Hygromycin. Cells were seeded at a 
concentration of 10,000 cells/well into white clear-bottom 96-well microplate, and allowed to 
attach overnight. The next day, cells were incubated in hypoxic conditions (0.1% O2) in 
presence of not of complex 2a (from 0.01 ȝM to 20 ȝM), auranofin (from 0.01 ȝM to 20 ȝM) 
or DHA (from 0.01 ȝM to 3, 5, 10, 20 and 50 ȝM), and complex 3 (from 0.01 ȝM to 20 ȝM). 
After incubation at 37 °C for 7 hours, 100 ȝL ONE-Step luciferase assay reagent (BPS 
Bioscience,  Cat # 60690) was added and rocked at room temperature for over 15 minutes. Then 
the luminescence of each well was determined by CLARIOstar microplate reader (BMG 
Labtech, Offenburg, Germany) to quantify induction of HIF. 
 
8. Isobologram construction 
The isobologram analysis evaluates the nature of interaction of two drugs, i.e., drug A (e.g., 
complex 2a) and drug B (e.g., sorafenib), at a given effect level. The concentrations required to 
produce the given effect (e.g., Gi50) are determined for drug A (ICx, A) and drug B (ICx, B) and 
indicated on the x and y axes of a two-coordinate plot, forming the two points (ICx, A, 0) and (0, 
ICx, B). The line connecting these two points is the additivity line. Then, the concentrations of 
A and B contained in combination that provide the same effect, denoted as (CA, x, CB, x), are 
placed in the same plot. Synergy, additivity, or antagonism is indicated when (CA, x, CB, x) is 
located below, on, or above the line, respectively. 
Combination index (CI) is calculated by the following equation: 
 
A CI of less than, equal to, and more than 1 indicates synergy, additivity, and antagonism, 
respectively. 
S15 
 
 
 
9. Inhibition of mammalian TrxR 
To determine the inhibition of mammalian TrxR, an established microplate reader-based 
assay was performed with minor modifications 9. For this purpose, commercially available rat 
liver TrxR (Sigma-Aldrich, Cat # T9698) was used and diluted with distilled water to achieve 
3.5 U/mL. Complex 2a ZaV IUHVKO\ GLVVROYHG aV VWRFN VROXWLRQ LQ VWHULOH DMSO. 25 ȝL aliquot 
RI WKH HQ]\PH aQG HLWKHU 25 ȝL SRWaVVLXP SKRVSKaWH bXIIHU (SH 7.0) FRQWaLQLQJ FRPSOH[ 2a in 
JUaGHG FRQFHQWUaWLRQV RU 25 ȝL bXIIHU ZLWKRXW WKH FRPSOH[ bXt DMSO (positive control) were 
added. The resulting solution (final DMSO concentration of 0.5 % v/v) was incubated at 37 °C 
for 75 min with moderate shaking in a 96-ZHOO SOaWH. TR HaFK ZHOO, 225 ȝL RI WKH UHaFWLRQ 
mixture (1.0 mL reaction mixture consists RI 500 ȝL 100 PM SRWaVVLXP SKRVSKaWH bXIIHU SH 
7.0, 80 ȝL 100 PM EDTA VROXWLRQ SH 7.5, 20 ȝL 0.2 % BSA, 100 ȝL RI a 20 PM NADPH 
aQG 300 ȝL GLVWLOOHG ZaWHU) ZaV aGGHG aQG WKH UHaFWLRQ ZaV LQLWLaWHG LPPHGLaWHO\ b\ aGGLQJ 25 
ȝL RI 20 PM DTNB VROXWLRQ. AIWHU Whorough mixing, the formation of TNB was monitored by 
a microplate reader at 405 nm at 1 min intervals for 10 measurements. The increase of TNB 
concentration over time followed a linear tendency (r2  0.99), aQG WKH HQ]\PaWLF aFWLYLWLHV 
were calculated as the slopes (increase in absorbance per second). Non-interference with the 
assay components was confirmed by a negative control experiment using an enzyme-free test 
compound. IC50 values were calculated as the concentration of the compound decreasing the 
enzymatic activity of the untreated control by 50%. 
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Supplementary Figure 1. Colony formation in bladder cancer T24 (top) and prostate cancer 
PC-3 (bottom) cells treated with increasing concentrations of complex 2a for 24 h and stained 
with crystal violet after 1 week of cultivation. 
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Supplementary Figure 2. ROS generation of DHA, Auranofin and 2a on a representative panel 
of cancer cell lineages (DCFH-DA assay). 
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Supplementary Figure 3. Inhibitory effects of Auranofin, DHA, 3 and 2a compounds on NF-
țB and HIF transcriptional activities in A549 and HeLa cancer cell models, respectively. 
a, kinetic of NF-țB activation by TNFĮ in A549 lung cancer cell model in which NF-țB 
luciferase reporter construct is stably integrated; b, the NF-țB inhibitory effect of the described 
compounds was evaluated in NF-țB/A549 reporter activity in response to 7h of treatment with 
TNFĮ; c, the HIF inhibitory effect of the described compounds was evaluated in HIF Luciferase 
Reporter Hela in response to hypoxia (0.1% O2). 
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Supplementary Figure 4. IC50 value of complex 2a towards isolated mammalian TrxR. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
